Thrombosis

Latest News

Dabigatran Safe, Effective for Managing VTE in Pediatric Trials

The open label, randomized, multicenter, phase 2b/3 DIVERSITY trial evaluated the efficacy and safety of dabigatran compared with SOC (low molecular weight heparin or vitamin K antagonist) in 240 children.

Risk Factors for Recurrent Venous Thromboembolism in Sickle Cell Disease

Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.

PV Stenosis May Predict Mortality in Bronchopulmonary Dysplasia and PH

The severity of lung disease in preterm infants with bronchopulmonary dysplasia and pulmonary hypertension undergoing cardiac catheterization did not correlate with mortality.

Red Cell Distribution Width May Be a Biomarker for Early Pulmonary Hypertension

Red cell distribution width may help detect early incident PH in patients who are at high risk for PH development.

Using Neural Networks to Assess Risk for Deep Vein Thrombosis

The neural network developed in this study yielded a false-negative rate of 0.22%.

Higher VTE Risk Associated Most With Older Age, Smoking, and Adiposity

Investigators examined a link between major cardiovascular risk factors, such as older age and smoking, and venous thromboembolism, consisting of deep vein thrombosis or pulmonary embolism.

Higher Risk for VTE With Oral vs Transdermal Hormone Replacement Therapy

Oral preparations of hormone replacement therapy for the treatment of menopausal symptoms are associated with a greater risk for VTE compared with transdermal formulations.

ASH Develops Practice Guidelines for Venous Thromboembolism

The American Society of Hematology has developed new guidelines for the treatment of venous thromboembolism.

Apixaban Prevents VTE in Patients With Malignancies Initiating Chemotherapy

Among patients with cancer starting chemotherapy who are at intermediate-to-high risk, rates of venous thromboembolism are significantly lower for thromboprophylaxis with apixaban versus placebo.

Rivaroxaban Supplemental New Drug Application Submitted to FDA for VTE Prophylaxis

The sNDA submission was supported by Phase 3 data from the MAGELLAN and MARINER trials which assessed the use of rivaroxaban in preventing VTE in acute medically ill patients while hospitalized and immediately after discharge.